October 31, 2018 / 8:45 PM / 13 days ago

BRIEF-Abbvie Announces Positive Results From Cll14

Oct 31 (Reuters) - AbbVie Inc:

* ABBVIE ANNOUNCES POSITIVE RESULTS FROM CLL14, A PHASE 3 TRIAL EVALUATING A VENETOCLAX COMBINATION AS FIRST-LINE THERAPY WITH A FIXED DURATION OF TREATMENT IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA

* ABBVIE INC - RANDOMIZED PHASE 3 TRIAL MET PRIMARY ENDPOINT

* ABBVIE INC - RANDOMIZED PHASE 3 TRIAL MET PRIMARY ENDPOINT, DEMONSTRATING PATIENTS TREATED WITH VENETOCLAX PLUS OBINUTUZUMAB HAD SUPERIOR PFS

* ABBVIE - PRELIMINARY ANALYSIS SUGGESTS SAFETY PROFILE SEEN IN VENETOCLAX PLUS OBINUTUZUMAB CONSISTENT WITH KNOWN SAFETY PROFILE OF EACH MEDICINE ALONE

* ABBVIE INC - RESULTS FROM CLL14 TRIAL WILL BE PRESENTED AT A FUTURE MEDICAL MEETING Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below